🧾 What This Document Is

This is a Definitive Proxy Statement (DEF 14A) for Enovis Corporation. Think of it as an invitation and information packet for the company's Annual Meeting of Stockholders. It's a mandatory SEC filing that gives shareholders the details they need to vote on key issues. The meeting is set for Tuesday, May 19, 2026, at 12:00 p.m. Eastern Time, held virtually.

👉 In simple terms: This is the company's "annual report card and request for votes." It tells shareholders what happened, who's running the show, and asks for their approval on several important matters.

🏢 What The Company Does

Enovis Corporation (NYSE: ENOV) is a medical technology company.

👉 In simple terms, they create and sell products for orthopedics (like joint replacements and surgical tools) to help people with bone and muscle issues live more active lives. They focus on innovation to get better patient outcomes.

🗳️ The 4 Key Votes (The "Agenda")

Shareholders are asked to vote on four main proposals at the meeting:

Elect 10 Directors: Choose the people who will oversee the company.
Ratify the Auditor: Approve hiring Ernst & Young LLP as the independent accounting firm for 2026.
"Say-on-Pay": Give an advisory (non-binding) approval of executive compensation.
Amend the Incentive Plan: Approve changes to the 2020 Omnibus Incentive Plan, which governs how stock awards are given to employees and directors.

👉 The Board recommends voting FOR all four proposals.

👥 Meet the Board Nominees

The company is electing a full slate of 10 directors. Here’s a quick look at the team:

Sharon Wienbar (Chair, Age 64): Former venture capitalist with deep tech and board leadership experience.
Damien McDonald (Age 61): The new CEO of Enovis (as of 2025), with 35+ years in the medical device industry.
Barbara W. Bodem (Age 58): Former CFO with strong finance and healthcare expertise.
Liam J. Kelly (Age 59): Former CEO of Teleflex, bringing extensive international med-tech experience.
Angela S. Lalor (Age 60): Former top HR executive at Danaher, focusing on talent and culture.
Philip A. Okala (Age 57): Hospital system COO with operational healthcare expertise.
Christine Ortiz (Age 55): MIT professor specializing in biotech and innovation.
A. Clayton Perfall (Age 67): Former CEO and audit committee chair with M&A and finance background.
Brady R. Shirley (Age 60): Former President & COO of Enovis, with deep company and industry knowledge.
Rajiv Vinnakota (Age 55): President of a leadership foundation, long-serving board member.

Why it matters: This board is described as "refreshed" (5 new members since 2022) and heavily weighted with direct industry (9/10) and former CEO/CFO/COO experience (9/10). They believe this mix provides strong oversight.

⚖️ How the Company is Governed

Enovis highlights several governance strengths:

Independent Board: 8 out of 10 nominees are independent. The Board Chair, Sharon Wienbar, is independent.
Strong Committees: The board has three key committees: Audit, Compensation & Human Capital Management (CHCM), and Nominating & Governance.
Risk Oversight: The board actively oversees major risks, including cybersecurity (quarterly updates) and compensation practices that might encourage excessive risk-taking.
Robust Policies: They have anti-hedging, anti-pledging, and clawback policies (which let them reclaim executive pay if financial results are later restated).

💰 Executive Compensation Snapshot

The filing details how top executives are paid. The philosophy is to link pay to performance and long-term stockholder value.

For 2025, the top-paid executives (Named Executive Officers) were:

Brady R. Shirley (Former President/COO): Total compensation of $7.8 million (includes a large portion from prior roles and severance-related items).
Damien McDonald (CEO, from 2025): Total compensation of $7.1 million for 2025.
Other executives' totals ranged from ~$2.5M to $4.3M.

A significant portion of pay is "at-risk" and based on:

Annual Cash Bonus: Tied to hitting financial and operational goals.
Long-Term Equity: A mix of performance-based stock units (PRSUs) and time-based stock units (RSUs) to align with shareholder interests over multiple years.

👉 Key Takeaway: The structure is designed to pay more for better company performance over the long run. Shareholders are being asked to vote on whether they approve of this structure ("Say-on-Pay").

📦 The Equity Plan Amendment

Proposal 4 asks shareholders to approve an amendment to the 2020 Omnibus Incentive Plan. The main change is to increase the number of shares available for grants by 3.5 million shares.

Why it matters: Companies use these plans to award stock to attract and retain talent. The company states that without this increase, they risk running out of available shares, which could hurt their ability to compete for top executives and employees. They emphasize that the burn rate (how quickly they use shares) is in line with their peers.

🌍 Corporate Responsibility & Culture

The proxy dedicates space to Enovis's values:

Safety First: Board reviews safety initiatives at every meeting.
Environmental Efforts: They track energy use and greenhouse gas emissions.
Human Capital: They conduct annual employee engagement surveys, have a Global Human Rights Policy, and prohibit child/forced labor.
Data Security: They have a global privacy program and regular cybersecurity training.

🧠 The Analogy

Think of this proxy statement like the program and ballot for a major nonprofit's annual gala. It introduces the board of directors (the gala's hosts), summarizes last year's activities (the annual report), outlines the budget and auditor (the financial review), and asks the members (shareholders) to vote on approving the leadership slate and key initiatives for the year ahead.

🧩 Final Takeaway

This document is about accountability and future planning. Enovis is seeking shareholder approval for its leadership team (the board), its financial watchdog (the auditor), its executive pay philosophy, and its plan to keep incentivizing employees with stock. The underlying message is a request for trust to continue executing its strategy in the competitive med-tech space.

Enovis CORP — DEF 14A Filing